Phaseline

Companies › Prestige Biopharma

Prestige Biopharma: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bevacizumab (HD204)
Vascular endothelial growth factor A inhibitor
VEGFAPhase 3Lung Cancer–
PBP1510
Anti-PAUF monoclonal antibody
PAUFPhase 1Pancreatic CancerDec 2026
Adalimumab (PBP1502)
TNF-alpha inhibitor
TNFPhase 1Healthy VolunteersJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03390686Bevacizumab (HD204)Phase 3Lung CancerOncologyJul 2024
NCT05141149PBP1510Phase 1Pancreatic CancerOncologyDec 2026
NCT05108259Adalimumab (PBP1502)Phase 1Healthy VolunteersOtherJun 2027

From the company's SEC filings

Cash of $47m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

VEGFA (1) PAUF (1) TNF (1)

Companies with the same targets

Roche Jiangsu Simcere Pharmaceutical Chengdu Origen Biotechnology Biotheus AstraZeneca Avirmax Biopharma Eli Lilly 4D Molecular Therapeutics PPD Development, LP Shanghai Henlius Biotech

Companies built like this

Nurix Therapeutics Exelixis Immunocore Genmab Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.